A5020864225- Skin Diseases and Diabetes
- Peripheral Neuropathies and Disorders
- Dermatologic Treatments and Research
- Nanocluster Synthesis and Applications
- Multiple Sclerosis Research Studies
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Cancer Mechanisms and Therapy
- Advanced biosensing and bioanalysis techniques
BIOCAD (Russia)
2023-2025
The search for new therapeutic options the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. article presents results double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on efficacy and safety divozilimab (BCD-132) SSc. Objective : to investigate patients with SSc compared placebo. Material methods . After enrolment study, received or placebo 48 weeks, after which they were switched open-label therapy until week 96. Results...
To assess the efficacy and safety of sampeginterferon-β1a (samPEG-IFN-β1a) 180 μg 240 administered once every 2 weeks compared to placebo low dose interferon beta-1a (LIB) 30 weekly.Patients with relapsing-remitting multiple sclerosis aged 18-60 years, Expanded Disability Status Scale score ≤5.5 were randomized at a ratio 2:2:2:1 following groups: samPEG-IFN-β1a µg, LIB, placebo. After 20 weeks, group completed study. week 52, final analysis was performed, which included primary endpoint...